Article Text

Download PDFPDF

91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors
  1. Federica Pecci1,
  2. Luca Cantini1,
  3. Valeria Cognigni1,
  4. Fabiana Perrone2,
  5. Veronica Agostinelli1,
  6. Giulia Mazzaschi2,
  7. Elda Favari2,
  8. Michele Maffezzoli2,
  9. Alessio Cortellini3,
  10. Francesca Rossi1,
  11. Rebecca Chiariotti1,
  12. Francesco Venanzi1,
  13. Giulia Mentrasti1,
  14. Giuseppe Lo Russo4,
  15. Giulia Galli4,
  16. Claudia Proto4,
  17. Monica Ganzinelli4,
  18. Francesca Tronconi1,
  19. Francesca Morgese1,
  20. Carla Campolucci5,
  21. Marco Moretti5,
  22. Arianna Vignini1,
  23. Melissa Bersanelli6,
  24. Sebastiano Buti2 and
  25. Rossana Berardi1
  1. 1Università Politecnica delle Marche, Ancona, MA, USA
  2. 2University of Parma, Parma, Italy
  3. 3Imperial College London, London, UK
  4. 4IRCCS Istituto Nazionale dei Tumori, Milano, Italy
  5. 5A.O.U. Ospedali Riuniti, Ancona, Italy
  6. 6University Hospital of Parma, Parma, Italy


Background Components of lipid profile seem to impact differently on phenotype and activity of immune cells in cancer.1,2 Their prognostic role in solid cancer patients treated with immune checkpoint inhibitors (ICIs) is still matter of debate.

Methods We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile [total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDL), high-density lipoproteins (HDL)] of consecutive solid cancer patients treated with ICIs and we investigated their impact on clinical outcomes. Cut-off values showing alteration of plasma lipid profile were ≥200 mg/dl for TC, ≥170 mg/dl for TGs, ≥130 mg/dl for LDL, <40 mg/dl for HDL in males, <45 mg/dl for HDL in females.

Results Among 432 patients enrolled, 67% (N=289) were men, 61% (N=266) were diagnosed with advanced non-small cell lung cancer and 86.6% (N=374) of patients were treated with ICIs as monotherapy. Patients’ circulating lipid assessments were described in tables (tables 1–3). At a median follow-up of 46 months, patients with TC≥200 mg/dl showed an improved, although not significant, progression free survival (PFS) (6.61 versus 4.67 months, p=0.4) and longer overall survival (OS) (19.4 versus 10.8 months, p=0.02) compared to those with TC<200 mg/dl. Conversely, patients with TGs≥170 mg/dl showed a shorter PFS (2.8 versus 5.07 months, p=0.006) and OS (5.92 versus 12.99 months, p<0.001) compared to those with TGs<170 mg/dl. Then, we combined TC and TGs in a LIPID-score that identified three subgroups: good risk (GR) (TC≥200 mg/dl and TGs<170 mg/dl), intermediate risk (IR) (TC<200 mg/dl and TGs<170 mg/dl or TC≥200 mg/dl and TGs≥170 mg/dl) and poor risk (PR) (TC<200 mg/dl and TGs≥170 mg/dl). The median PFS of GR, IR and PR groups was 7.76, 4.18 and 2.40 months, respectively (p<0.001). Moreover, median OS of GR, IR and PR was 20.36, 11.18 and 4.14 months, respectively (p<0.001) (figure 1). At multivariate analyses, after adjusting for baseline performance status, histology, treatment line, sex, statin use, number of metastatic sites and body mass index, the impact of LIPID score remained significant for both PFS and OS (table 4). Looking at TC components, HDL and LDL, a significant association was detected only for HDL and OS, with patients characterized by higher HDL levels showing longer OS (15.3 vs 10.1 months, p=0.02).

Conclusions LIPID score seems to strongly define subgroups of patients treated with ICIs with different prognosis. Further mechanistic insights are needed to clarify the prognostic and predictive role of lipid profile components in patients treated with ICIs.


  1. Howie D, Ten Bokum A, Necula AS, Cobbold SP, Waldmann H. The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival. Front Immunol. 2018;8:1949. Published 2018 Jan 12. doi:10.3389/fimmu.2017.01949

  2. Bonacina F, Coe D, Wang G, et al. Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. Nat Commun. 2018;9(1):3083. Published 2018 Aug 6. doi:10.1038/s41467-018-05322-1

Ethics Approval Ethical approval to conduct this study was obtained by the respective local ethical committees on human experimentation of each participating center, after previous approval by the coordinating center (’Comitato Etico Regionale delle Marche – C.E.R.M.’, Reference Number 792). All study related procedures and data collection were conducted in accordance with the Declaration of Helsinki and in accordance with Good Clinical Practice.

Consent Not applicable

Abstract 91 Tables 1,2,3

Patients circulating lipid assessment

Abstract 91 Table 4

Multivariate analysis for PFS and OS

Abstract 91 Figure 1

PFS and OS according to LIPID scoreGR, good risk; IR, intermediate risk; PR, poor risk

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.